MDR System Adequate For Knee Prostheses Adverse Events, Agency Says
This article was originally published in The Gray Sheet
Executive Summary
FDA's medical device reporting system is adequate for reporting adverse events that might occur with fixed-bearing, cementless femoro-tibial unicompartmental knee prostheses, the agency says in a March 7 preliminary notice to downclassify the devices from Class III to Class II.
You may also be interested in...
Knee prostheses
FDA's special controls guidance for knee joint patellofemorotibial and femorotibial metal/polymer porous-coated uncemented prostheses posted Feb. 7 identifies four risks associated with the devices: adverse tissue reaction, infection, pain and/or loss of function and revision surgery. FDA issued a preliminary notice announcing its intent to downclassify the devices from Class III to Class II in March 2000 (1"The Gray Sheet" March 13, 2000, p. 9)...
Knee prostheses
FDA's special controls guidance for knee joint patellofemorotibial and femorotibial metal/polymer porous-coated uncemented prostheses posted Feb. 7 identifies four risks associated with the devices: adverse tissue reaction, infection, pain and/or loss of function and revision surgery. FDA issued a preliminary notice announcing its intent to downclassify the devices from Class III to Class II in March 2000 (1"The Gray Sheet" March 13, 2000, p. 9)...
FDA Sides With Panel In Downclassifying Antimicrobial Susceptibility Devices
FDA will likely not require additional post-market surveillance from companies manufacturing automated short-term incubation cycle (STIC) antimicrobial susceptibility devices (ASDs), the agency says in the March 8 Federal Register.